Recent advances in pharmacological treatment of psychosis in late life

Current Opinion in Psychiatry

Volumn 24, Issue 6, 2011, Pages 455-460

  Chan, Wai Chi ^a   Lam, Linda Chiu Wa ^b   Chen, Eric Yu Hai ^c  

^a SHATIN HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMAVANSERIN; QUETIAPINE; RISPERIDONE;

AGITATION; AGRANULOCYTOSIS; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; COCHRANE LIBRARY; DELIRIUM; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GERIATRIC PATIENT; HUMAN; HYPOTENSION; INTESTINE OBSTRUCTION; LOW DRUG DOSE; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATIENT COMPLIANCE; PSYCHOSIS; PSYCINFO; REVIEW; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOM; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPSYCHOTIC AGENTS; DELIRIUM; DEMENTIA; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 80053386363     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32834a3f47     Document Type: Review

References (44)

1. United Nations Population Division. World Population Ageing 2009. New York: United Nations; 2010.
2. Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr 2010; 22:1025-1039.
3. Qiu WQ, Dean M, Liu T, et al. Physical and mental health of homebound older adults: an overlooked population. J Am Geriatr Soc 2010; 58:2423-2428.
4. Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002; 59:53-59. (Pubitemid 34044405)
5. Sigstrom R, Skoog I, Sacuiu S, et al. The prevalence of psychotic symptoms and paranoid ideation in nondemented population samples aged 70-82 years. Int J Geriatr Psychiatry 2009; 24:1413-1419.
6. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010; 22:346-372.
7. Meesters PD, de Haan L, Comijs HC, et al. Schizophrenia spectrum disorders in later life. Am J Geriatr Psychiatry 2011. [Epub ahead of print]
8. Marriott R, Neil W, Waddingham S. Antipsychotic medication for elderly people with schizophrenia. Cochrane Database Syst Rev 2006; (1): CD005580. doi: 10.1002/14651858.CD005580.
9. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26:783-790.
10. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008; 16:31-43.
11. Riedel M, Eich FX, Moller HJ. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur Psychiatry 2009; 24:149-153.
12. Singh D, O'Connor DW. Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clin Interv Aging 2009; 4:351-355.
13. Coley KC, Scipio TM, Ruby C, et al. Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients. J Psychiatr Pract 2009; 15:150-153.
14. Ritchie CW, Harrigan S, Mastwyk M, et al. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 31/2 years duration. Int J Geriatr Psychiatry 2010; 25:411-418.
15. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197:174-179.
16. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170:96-103.
17. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011; 68:190-197.
18. Food and Drug Administration. Antipsychotics: conventional and atypical. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm110212.htm. [Accessed 1 May 2011]
19. European Medicines Agency: CHMP Pharmacovigilance Working Party. Antipsychotics and cerebrovascular accident. http://www.mhra.gov.uk/home/groups/ pl-p/documents/websiteresources/con2024914.pdf. [Accessed May 2011]
20. Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease. J Clin Psychopharmacol 2010; 30:40-43.
21. Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin 2008; 24:657-722.
22. MsCusker J, Cole MG, Voyer P, et al. Prevalence and incidence of delirium in long-term care. Int J Geriatr Psychiatry 2011. [Epub ahead of print]
23. Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev 2008, (1): CD005317. doi: 10.1002/14651858.CD005317. pub2. (Pubitemid 351807509)
24. Lonergan E, Luxenberg J, Areosa Sastre A. Benzodiazepines for delirium. Cochrane Database Syst Rev 2009, (4): CD006379. doi: 10.1002/14651858.CD006379. pub3.
25. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev 2007, (2): CD005594. doi: 10.1002/14651858.CD005594. pub2. (Pubitemid 351805712)
26. Briskman I, Dubinski R, Barak Y. Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomes. Int Psychogeriatr 2010; 22:328-331.
27. Kim SW, Yoo JA, Lee SY, et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol Clin Exp 2010; 25:298-302.
28. Devlin JW,Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419-427.
29. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289:12-17.
30. Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry 2011. [Epub ahead of print]
31. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996-1002.
32. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother 2010; 8:316-330.
33. Marras C, Gruneir A, Wan X, et al. Antipsychotics and mortality in Parkinsonism. Am J Geriatr Psychiatry 2011. [Epub ahead of print]
34. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of Parkinsonian patients with visual hallucinations. Mov Disord 2010; 25:1399-1408.
35. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35:881-892.
36. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20:177-184.
37. Shah SM, Carey IM, Harris T, et al. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry 2011; 26:423-434.
38. Lipscombe LL, Levesque LE, Gruneir A, et al. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry 2011. [Epub ahead of print]
39. Narula PK, Rehan HS, Unni KES, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010; 118:218-223.
40. McKibbin CL, Golshan S, Griver K, et al. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis. Schizophr Res 2010; 121:203-206.
41. Mehta S, Chen H, Johnson M, Aparasu RR. Risk of serious cardiac events in older adults using antipsychotic agents. Am J Geriatr Pharmacother 2011; 9:120-132.
42. Parabiaghi A, D?Avanzo B, Tettamanti M, et al. The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. Contemp Clin Trials 2011. [Epub ahead of print]
43. Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010; 10:26-38.
44. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364:842-851.